Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials

Cancer Letters

Volumn 347, Issue 2, 2014, Pages 175-182

  Athanasoula, Kalliopi Ch ^a   Gogas, Helen ^a   Polonifi, Katerina ^a   Vaiopoulos, Aristeidis G ^a   Polyzos, Aristidis ^a   Mantzourani, Marina ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anti apoptotic protein; Cancer; IAP family; Survivin; Targeted therapy

Indexed keywords

CARBOPLATIN; DOCETAXEL; GATAPARSEN; PACLITAXEL; PREDNISONE; SEPANTRONIUM BROMIDE; SMALL INTERFERING RNA; SURVIVIN; TERAMEPROCOL;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL DEATH; CELL DIVISION; DRUG RESPONSE; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INTERPHASE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MITOSIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TUMOR BIOPSY;

ANTI-APOPTOTIC PROTEIN; CANCER; IAP FAMILY; SURVIVIN; TARGETED THERAPY;

CARCINOGENESIS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS;

EID: 84898444850     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.014     Document Type: Review

References (104)

1. Andersen M.H., Svane I.M., Becker J.C., Straten P.T. The universal character of the tumor-associated antigen survivin. Clin. Cancer Res. 2007, 13:5991-5994.
2. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:49-60.
3. Vucic D., Fairbrother W.J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 2007, 13:5995-6000.
4. Bongiovanni L., Muller E.J., Della Salda L. Survivin in skin pathologies. Exp. Dermatol. 2011, 20:457-463.
5. Yamamoto H., Ngan C.Y., Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99:1709-1714.
6. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011, 10:35.
7. Necochea-Campion R., Chen C.S., Mirshahidi S., Howard F.D., Wall N.R. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett. 2013, 339:167-174.
8. Caldas H., Jiang Y., Holloway M.P., Fangusaro J., Mahotka C., Conway E.M., Altura R.A. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24:1994-2007.
9. Caldas H., Fangusaro J.R., Boue D.R., Holloway M.P., Altura R.A. Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood 2007, 109:1479-1489.
10. Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., Wheatley S.P. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J. Biol. Chem. 2006, 281:1286-1295.
11. Lladser A., Sanhueza C., Kiessling R., Quest A.F. Is survivin the potential Achilles' heel of cancer?. Adv. Cancer Res. 2011, 111:1-37.
12. Caldas H., Honsey L.E., Altura R.A. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol. Cancer 2005, 4:11.
13. Pavlidou A., Dalamaga M., Kroupis C., Konstantoudakis G., Belimezi M., Athanasas G., Dimas K. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J. Gastroenterol. 2011, 17:1614-1621.
14. Fangusaro J.R., Caldas H., Jiang Y., Altura R.A. Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr. Blood Cancer 2006, 47:4-13.
15. Zheng W.Y., Kang Y.Y., Li L.F., Xu Y.X., Ma X.Y. Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discov. Ther. 2011, 5:293-298.
16. Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., Kopantzev E.P., Shakhparonov M.I. Survivin monomer plays an essential role in apoptosis regulation. J. Biol. Chem. 2011, 286:23296-23307.
17. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
18. Altieri D.C. New wirings in the survivin networks. Oncogene 2008, 27:6276-6284.
19. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 1998, 152:43-49.
20. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., Choo K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000, 10:1319-1328.
21. Liu R., Mitchell D.A. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunol. Immunother. 2010, 59:183-193.
22. Chowdhury S., Howell G.M., Teggart C.A., Chowdhury A., Person J.J., Bowers D.M., Brattain M.G. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J. Biol. Chem. 2011, 286:30937-30948.
23. Lechler P., Schaumburger J., Kock F.X., Balakrishnan S., Doukas S., Prantl L., Grifka J. The oncofetal gene survivin promotes cell proliferation and survival in primary human osteoblastic cells. Calcif. Tissue Int. 2011, 89:211-220.
24. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5:1087-1098.
25. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc. Natl. Acad. Sci. USA 2005, 102:11480-11485.
26. Lechler P., Balakrishnan S., Schaumburger J., Grassel S., Baier C., Grifka J., Straub R.H., Renkawitz T. The oncofetal gene survivin is re-expressed in osteoarthritis and is required for chondrocyte proliferation in vitro. BMC Musculoskelet. Disord. 2011, 12:150.
27. Dallaglio K., Marconi A., Pincelli C. Survivin: a dual player in healthy and diseased skin. J. Invest. Dermatol. 2012, 132:18-27.
28. Bokarewa M., Lindblad S., Bokarew D., Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res. Ther. 2005, 7:R349-R358.
29. Ge Q.X., Li Y.Y., Nie Y.Q., Zuo W.G., Du Y.L. Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med. Oncol. 2013, 30:535.
30. Wang Z., Fukuda S., Pelus L.M. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004, 23:8146-8153.
31. Esteve P.O., Chin H.G., Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc. Natl. Acad. Sci. USA 2005, 102:1000-1005.
32. Groner B., Weiss A. Targeting survivin in cancer: novel drug development approaches. BioDrugs 2013.
33. Ma Q., Wang X., Li Z., Li B., Ma F., Peng L., Zhang Y., Xu A., Jiang B. MicroRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol. Rep. 2013, 29:1652-1658.
34. Alajez N.M., Lenarduzzi M., Ito E., Hui A.B., Shi W., Bruce J., Yue S., Huang S.H., Xu W., Waldron J., O'Sullivan B., Liu F.F. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer. Res. 2011, 71:2381-2391.
35. Acquati S., Greco A., Licastro D., Bhagat H., Ceric D., Rossini Z., Grieve J., Shaked-Rabi M., Henriquez N.V., Brandner S., Stupka E., Marino S. Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells 2013, 31:190-202.
36. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
37. Ghosh J.C., Dohi T., Kang B.H., Altieri D.C. Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 2008, 283:5188-5194.
38. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C., Altieri D.C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 2003, 100:13791-13796.
39. White-Gilbertson S., Kurtz D.T., Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Mol. Oncol. 2009, 3:402-408.
40. Lens S.M., Vader G., Medema R.H. The case for survivin as mitotic regulator. Curr. Opin. Cell Biol. 2006, 18:616-622.
41. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131:271-285.
42. Kelly A.E., Ghenoiu C., Xue J.Z., Zierhut C., Kimura H., Funabiki H. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010, 330:235-239.
43. van der Waal M.S., Hengeveld R.C., van der Horst A., Lens S.M. Cell division control by the Chromosomal Passenger Complex. Exp. Cell. Res. 2012, 318:1407-1420.
44. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 2006, 18:609-615.
45. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., Symons M., Altieri D.C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002, 62:2462-2467.
46. Connell C.M., Colnaghi R., Wheatley S.P. Nuclear survivin has reduced stability and is not cytoprotective. J. Biol. Chem. 2008, 283:3289-3296.
47. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin. Invest. 2004, 114:1117-1127.
48. Gerl R., Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005, 26:263-270.
49. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., Bus C.J., Kadkhoda K., Wiechec E., Halayko A.J., Los M. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46:497-510.
50. Miura K., Fujibuchi W., Ishida K., Naitoh T., Ogawa H., Ando T., Yazaki N., Watanabe K., Haneda S., Shibata C., Sasaki I. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg. Today 2010, 41:175-182.
51. Liu T., Brouha B., Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004, 23:39-48.
52. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430:199-205.
53. Knight B.B., Oprea-Ilies G.M., Nagalingam A., Yang L., Cohen C., Saxena N.K., Sharma D. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr. Relat. Cancer 2011, 18:413-428.
54. Mehrotra S., Languino L.R., Raskett C.M., Mercurio A.M., Dohi T., Altieri D.C. IAP regulation of metastasis. Cancer Cell 2010, 17:53-64.
55. McKenzie J.A., Liu T., Goodson A.G., Grossman D. Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res. 2010, 70:7927-7937.
56. Khan S., Aspe J.R., Asumen M.G., Almaguel F., Odumosu O., Acevedo-Martinez S., De Leon M., Langridge W.H., Wall N.R. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br. J. Cancer 2009, 100:1073-1086.
57. Khan S., Jutzy J.M., Aspe J.R., McGregor D.W., Neidigh J.W., Wall N.R. Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12.
58. Mera S., Magnusson M., Tarkowski A., Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J. Leukoc. Biol. 2008, 83:149-155.
59. Hofmann U.B., Voigt H., Andersen M.H., Straten P.T., Becker J.C., Eggert A.O. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur. J. Immunol. 2009, 39:1419-1424.
60. Bowen A.R., Hanks A.N., Allen S.M., Alexander A., Diedrich M.J., Grossman D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J. Invest. Dermatol. 2003, 120:48-55.
61. Roca H., Craig M.J., Ying C., Varsos Z.S., Czarnieski P., Alva A.S., Hernandez J., Fuller D., Daignault S., Healy P.N., Pienta K.J. IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. J. Cell. Biochem. 2012, 113:1569-1580.
62. Wang Q.P., Wang Y., Wang X.D., Mo X.M., Gu J., Lu Z.Y., Pan Z.L., Zhu Y.X. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-kappaB expression in MCF-7/5-FU cells. Int. J. Biochem. Cell Biol. 2013, 45:2036-2044.
63. Zhang T., Fields J.Z., Opdenaker L., Otevrel T., Masuda E., Palazzo J.P., Isenberg G.A., Goldstein S.D., Brand M., Boman B.M. Survivin-induced Aurora-B kinase activation: a mechanism by which APC mutations contribute to increased mitoses during colon cancer development. Am. J. Pathol. 2010, 177:2816-2826.
64. Kim K., Chie E.K., Wu H.G., Kim S.G., Lee S.H., Kang G.H., Hyun C.L., Ha S.W. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int. J. Colorectal Dis. 2011, 26:1019-1023.
65. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi N., Frati L., Agliano A.M. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 2003, 21:306-312.
66. Jeon C., Kim M., Kwak C., Kim H.H., Ku J.H. Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS ONE 2013, 8:e76719.
67. Lv S., Turlova E., Zhao S., Kang H., Han M., Sun H.S. Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumour Biol. 2013.
68. Song J., Su H., Zhou Y.Y., Guo L.L. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013, 34:2053-2062.
69. Sun P.L., Jin Y., Kim H., Seo A.N., Jheon S., Lee C.T., Chung J.H. Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch. 2013, 463:427-436.
70. Samm N., Werner K., Ruckert F., Saeger H.D., Grutzmann R., Pilarsky C. The role of apoptosis in the pathology of pancreatic cancer. Cancers 2010, 3:1-16.
71. Liu J.L., Gao W., Kang Q.M., Zhang X.J., Yang S.G. Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PLoS ONE 2013, 8:e71930.
72. Kucukgoz Gulec U., Gumurdulu D., Guzel A.B., Paydas S., Seydaoglu G., Acikalin A., Khatib G., Zeren H., Vardar M.A., Altintas A. Prognostic importance of survivin, Ki-67, and topoisomerase IIalpha in ovarian carcinoma. Arch. Gynecol. Obstet. 2013.
73. Chen N., Gong J., Chen X., Meng W., Huang Y., Zhao F., Wang L., Zhou Q. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. Hum. Pathol. 2009, 40:950-956.
74. Xie Y.L., An L., Jiang H., Wang J. Nuclear survivin expression is associated with a poor prognosis in Caucasian non-small cell lung cancer patients. Clin. Chim. Acta. 2012, 414:41-43.
75. Hui M.K., Lai K.K., Chan K.W., Luk J.M., Lee N.P., Chung Y., Cheung L.C., Srivastava G., Tsao S.W., Tang J.C., Law S. Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med. Oncol. 2012, 29:3009-3016.
76. Vandghanooni S., Eskandani M., Montazeri V., Halimi M., Babaei E., Feizi M.A. Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J. Cancer Res. Ther. 2011, 7:325-330.
77. Ryan B., O'Donovan N., Browne B., O'Shea C., Crown J., Hill A.D., McDermott E., O'Higgins N., Duffy M.J. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br. J. Cancer 2005, 92:120-124.
78. Xi R.C., Biao W.S., Gang Z.Z. Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie 2011, 34:428-432.
79. Ku J.H., Godoy G., Amiel G.E., Lerner S.P. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012, 110:630-636.
80. Guindalini R.S., Mathias Machado M.C., Garicochea B. Monitoring survivin expression in cancer: implications for prognosis and therapy. Mol. Diagn. Ther. 2013, 17:331-342.
81. Kanwar J.R., Kamalapuram S.K., Kanwar R.K. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 2011, 16:485-494.
82. Carrasco R.A., Stamm N.B., Marcusson E., Sandusky G., Iversen P., Patel B.K. Antisense inhibition of survivin expression as a cancer therapeutic. Mol. Cancer Ther. 2011, 10:221-232.
83. Church D.N., Talbot D.C. Survivin in solid tumors: rationale for development of inhibitors. Curr. Oncol. Rep. 2012, 14:120-128.
84. Talbot D.C., Ranson M., Davies J., Lahn M., Callies S., Andre V., Kadam S., Burgess M., Slapak C., Olsen A.L., McHugh P.J., de Bono J.S., Matthews J., Saleem A., Price P. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 2010, 16:6150-6158.
85. Wiechno P., Somer B.G., Mellado B., Chlosta P.L., Cervera Grau J.M., Castellano D., Reuter C., Stockle M., Kamradt J., Pikiel J., Duran I., Wedel S., Callies S., Andre V., Hurt K., Brown J., Lahn M., Heinrich B. A randomised phase 2 study combining LY2181308 sodium (Survivin Antisense Oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur. Urol. 2013.
86. Hansen J.B., Fisker N., Westergaard M., Kjaerulff L.S., Hansen H.F., Thrue C.A., Rosenbohm C., Wissenbach M., Orum H., Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer. Ther. 2008, 7:2736-2745.
87. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
88. Trabulo S., Cardoso A.M., Santos-Ferreira T., Cardoso A.L., Simoes S., Pedroso de Lima M.C. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol. Pharm. 2011, 8:1120-1131.
89. Aspe J.R., Wall N.R. Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther. 2010, 3:247-254.
90. Weng Y., Fei B., Chi A.L., Cai M. Inhibition of gastric cancer cell growth in vivo by overexpression of adeno-associated virus-mediated survivin mutant C84A. Oncol. Res. 2013, 20:411-417.
91. Eustace A.J., Mahgoub T., Tryfonopoulos D., O'Donovan N., Crown J. Prospects for non-immunological molecular therapeutics in melanoma. J BUON 2010, 15:9-18.
92. Glaros T.G., Stockwin L.H., Mullendore M.E., Smith B., Morrison B.L., Newton D.L. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 2012, 70:207-212.
93. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., Tominaga F., Kinoyama I., Matsuhisa A., Kudou M., Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011, 102:614-621.
94. Kaneko N., Yamanaka K., Kita A., Tabata K., Akabane T., Mori M. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. Biol. Pharm. Bull. 2013, 36:1921-1927.
95. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., van Klaveren R.J., Chaudhary S., Gunther A., Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4481-4486.
96. Kelly R.J., Thomas A., Rajan A., Chun G., Lopez-Chavez A., Szabo E., Spencer S., Carter C.A., Guha U., Khozin S., Poondru S., Van Sant C., Keating A., Steinberg S.M., Figg W., Giaccone G. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013, 24:2601-2606.
97. Lewis K.D., Samlowski W., Ward J., Catlett J., Cranmer L., Kirkwood J., Lawson D., Whitman E., Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 2011, 29:161-166.
98. Tolcher A.W., Quinn D.I., Ferrari A., Ahmann F., Giaccone G., Drake T., Keating A., de Bono J.S. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann. Oncol. 2012, 23:968-973.
99. Khanna N., Dalby R., Tan M., Arnold S., Stern J., Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 2007, 107:554-562.
100. Grossman S.A., Ye X., Peereboom D., Rosenfeld M.R., Mikkelsen T., Supko J.G., Desideri S. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012, 14:511-517.
101. Bernatchez C., Zhu K., Li Y., Andersson H., Ionnides C., Fernandez-Vina M., Cano P., Cooper L., Abbruzzese J., Hwu P., Chang D.Z., Radvanyi L.G. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 2011, 29:3021-3030.
102. Jha K., Shukla M., Pandey M. Survivin expression and targeting in breast cancer. Surg. Oncol. 2011.
103. Altieri D.C. Targeting survivin in cancer. Cancer Lett. 2013, 332:225-228.
104. Becker J.C., Andersen M.H., Hofmeister-Muller V., Wobser M., Frey L., Sandig C., Walter S., Singh-Jasuja H., Kampgen E., Opitz A., Zapatka M., Brocker E.B., Thor Straten P., Schrama D., Ugurel S. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol. Immunother. 2012, 61:2091-2103.